NSC Drives Safety Awareness During National Safety Month
WASHINGTON, June 2, 2025 /PRNewswire/ -- The National Safety Council celebrates National Safety Month this June to increase awareness of the leading causes of preventable injuries and deaths.
Preventable injuries occur at alarming rates – in the U.S., someone dies from a preventable incident approximately every two minutes. In 2023, preventable injuries claimed 222,698 lives, representing a 154% increase from 1992. Additionally, more than 7,000 preventable injuries occur every hour across the country.
"For nearly three decades, National Safety Month has served as a vital landmark in the push to make people safer, from the workplace to anyplace," said Lorraine Martin, president and CEO of NSC. "Each year we, along with businesses and individuals across the country, take this month to encourage and educate others around safety at work, on the road and in our communities. Thank you to all those who partner with us to end preventable injuries and deaths each June and all year long."
Each week of June spotlights a different safety topic:
Week 1: Continuous Improvement
Week 2: Employee Engagement
Week 3: Roadway Safety
Week 4: Wellbeing
The National Safety Council observance of this year's National Safety Month is sponsored by EcoOnline. For free workplace safety resources including interactive quizzes, safety talks, graphics and more, visit nsc.org/nsm.
About the National Safety CouncilThe National Safety Council is America's leading nonprofit safety advocate – and has been for over 110 years. As a mission-based organization, we work to eliminate the leading causes of preventable death and injury, focusing our efforts on the workplace and roadways. We create a culture of safety to not only keep people safer at work, but also beyond the workplace so they can live their fullest lives.
Connect with NSC:FacebookTwitter LinkedIn YouTube Instagram
View original content to download multimedia:https://www.prnewswire.com/news-releases/nsc-drives-safety-awareness-during-national-safety-month-302471054.html
SOURCE National Safety Council
Errore nel recupero dei dati
Effettua l'accesso per consultare il tuo portafoglio
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
HoneyNaps Launches Cloud Version of AI Sleep Diagnostic Software "SOMNUM™" at SLEEP 2025
HIPAA-compliant cloud-based service provides diagnostic reports via the web with no installation required AI-powered trial service offered, highlighting potential for hospital-specific integration Presented performance of heart rate-based sleep stage estimation algorithm through oral and poster presentations BOSTON, Aug. 19, 2025 /PRNewswire/ -- HoneyNaps, a medical AI diagnostics company, showcased both its technological capabilities and research achievements at SLEEP 2025, the world's largest sleep medicine conference held in Seattle, USA, from June 8 to 11. SLEEP 2025 is a prestigious international conference co-hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), drawing approximately 5,000 sleep professionals and featuring over 1,000 of the latest research presentations. HoneyNaps has been the only Korean company to participate in the conference for four consecutive years since 2022. At this year's conference, the company further reinforced its academic credibility through both oral and poster presentations. Notably, in an oral presentation titled "Development and Evaluation of an Exclusively ECG-based Deep Learning Model for Sleep Staging," the company introduced a deep learning model that reliably classifies sleep stages using single-lead ECG signals, demonstrating significantly improved accuracy over conventional methods. At its exhibition booth, HoneyNaps drew attention by unveiling SOMNUM™ Cloud, an AI solution for automated analysis of polysomnography (PSG) data. Users can upload EDF files extracted from PSG devices to the cloud, where the AI engine automatically analyzes the data and generates a comprehensive report — easily downloadable online with no software installation required. During the conference, HoneyNaps offered a free trial consisting of three AI analyses, enabling visitors to experience SOMNUM Cloud in a clinical-like setting. The hands-on program was met with enthusiastic feedback from U.S. sleep physicians and RPSGTs (Registered Polysomnographic Technologists). Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, stated, "With its cloud-based architecture, streamlined implementation process, and HIPAA compliance, more than 100 U.S. medical institutions expressed interest in potential adoption. We also held individual meetings with leading global sleep companies to discuss potential strategic collaborations". For further information, please contact:HoneyNaps USA, Kwon / Managing DirectorEmail: sleep@ #517, SPACES, 361 Newbury Street, Boston, MA, 02115Website: View original content to download multimedia: SOURCE HoneyNaps Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Selonterra announces grant of United States patent on original discoveries in Alzheimer's disease
SAN MATEO, Calif., Aug. 19, 2025 /PRNewswire/ -- Selonterra, Inc. ( a biotechnology company developing transformative therapies for neurodegenerative disorders announces that the U.S. Patent and Trademark Office (USPTO) has granted the U.S. Patent No. 12,385,093 entitled "Use of APOE4 motif-mediated genes for diagnosis and treatment of Alzheimer's disease". Selonterra focuses on neurodegenerative disorders with strong genetic links, including Alzheimer's disease (AD). APOE4 is the most important genetic factor associated with late onset AD. We discovered that the single nucleotide change in APOE4 regulates the expression of genes in its chromosomal vicinity. These APOE4-motif mediated genes offer novel unexploited targets for the development of small molecule therapeutics for AD. "We relentlessly pursue intellectual property coverage along the entire development path from our early discoveries, through novel targets to small molecule composition of matter patents," said Roman Urfer, PhD, Founder and CEO of Selonterra. "The issuance of our patent around our newly discovered function of the APOE4 single nucleotide polymorphism is testament to our innovative strength," said Anne Urfer-Buchwalder, PhD, Founder and President of Selonterra. "These discoveries enable us to exploit the well-established APOE4 root cause of AD from a previously unappreciated angle." About Selonterra, Inc. Selonterra, Inc. ( pursues transformative approaches to the development of therapies of neurodegenerative disorders, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. We harness human genetics, molecular pathway analysis and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics. Selonterra's founders and advisors are scientists and executives with decades of biotech and pharma experience complemented by a global network of collaborator companies. Investor and Media Contact: T: (+1) 650 206 7025E: admin@ View original content to download multimedia: SOURCE Selonterra, Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Landmark Science announces research to be presented at ISPE 2025
At this year's conference, Landmark Science spotlights real-world evidence's power to drive GLP-1 and Wegovy insights in Medicare and shape regulatory decision-making. LOS ANGELES, Aug. 19, 2025 /PRNewswire/ -- Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in Washington D.C. Landmark Science's real-world data is featured across five pieces of research to be presented at the conference. The research provides a timely look into patient populations initiating GLP-1 receptor agonists (RAs), offering new insights into the characteristics of Medicare patients initiating these therapies. They also offer a special focus on Medicaid patients initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction — an area of growing importance as GLP-1 RAs expand beyond diabetes management. "GLP-1s are on the rise in Medicare — from Type 2 diabetes and obesity to cardiovascular risk reduction, kidney disease, obstructive sleep apnea, and noncirrhotic MASH, indications for GLP-1s have expanded fast. But not a lot is known about utilization in a Medicare population. Real-world evidence is essential in understanding prescribing patterns, patient outcomes, and safety profiles, ultimately guiding optimal care strategies and policy decisions for Medicare beneficiaries," said Shivani Aggarwal, CEO. "The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity," said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. "At ISPE, we're excited to share data that helps stakeholders better understand who is initiating these therapies — and who might be left behind." At this year's ISPE, Landmark epidemiologists are also generating novel methodologies that will shape the future of evidence generation used to support regulatory decision-making. "Our research uncovers nuanced trends and synthesizes them into transparent, evidenced based research—to showcase and drive the utility of real-world evidence in regulatory decision-making," said Shivani Aggarwal. Highlights include: Two poster presentations on Medicare beneficiaries initiating GLP-1 RAs and Wegovy. Two poster presentations underscoring RWE's potential for use in regulatory decision-making. A poster presentation introducing a framework operationalizing regulatory guidelines into key steps for submission success. Schedule a meeting with Landmark Science at ISPE 2025, and learn more about our abstracts and events, including workshops and panels. Follow Landmark Science on LinkedIn for more updates from #ISPE2025. Poster Discussions and Presentations Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-032 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population Focusing specifically on Wegovy, this analysis offers a more granular view into who Wegovy initiators are, how they responded, and what happened after Wegovy became an option for cardiovascular protection. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-033 Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs) Real-world evidence use is growing but still has mixed acceptance. Here we synthesize emerging patterns into actionable insights for success. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-079 Evaluation of Real-World Evidence in Regulatory and HTA Submissions Real-world evidence isn't judged the same everywhere — and the differences matter. We review feedback from regulatory and key HTA bodies to describe the acceptability of RWE in marketing applications. - Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-080 Framework for Real-World Data Used in Regulatory Submissions Discover our framework, which operationalizes regulatory guidelines about real-world data into key steps for submission readiness. - Tuesday Aug 26, 2025 | Hall D | Poster Session C: 12:00 PM – 1:30 PM- Poster Code: C-124 About Landmark Science, Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE to help patients. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, regulators, and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit or contact info@ Media Contact:Landmark Sciencemedia@ (424) 535-3011https:// View original content to download multimedia: SOURCE Landmark Science, Inc
